ASPIRE BIOPHARMA HOLDINGS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
ASPIRE BIOPHARMA HOLDINGS, INC. (ASBP) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $810.79 thousand for the 12-month period ending 2025-12-31, per its S-1/A filed 2026-04-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-04-10
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2025-12-31 | $810.79K S-1/A · filed 2026-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |